Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
Abstract Marzeptacog alfa (activated) (MarzAA) is an activated recombinant human FVII (rFVIIa) variant developed as subcutaneous (s.c.) administration for the treatment or prevention of bleeding episodes in patients with hemophilia A (HA) or hemophilia B (HB) with inhibitors and other rare bleeding...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , |
|---|---|
| Формат: | Ном |
| Хэвлэсэн: |
Wiley,
2022-12-01T00:00:00Z.
|
| Нөхцлүүд: | |
| Онлайн хандалт: | Connect to this object online. |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
Интернэт
Connect to this object online.3rd Floor Main Library
| Зохиогчийн тэмдэгт: |
A1234.567 |
|---|---|
| Хуулбар 1 | Бэлэн |